Metraipolis › archive › dc_de2ceca81ee2

Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes: a BRAVO model-based evaluation — Europe PMC PMID:42273622

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42273622
DOI: 10.3389/fpubh.2026.1787562
License (as archived): solo-consultazione
Archived: 2026-11-01T07:09:34.012Z
SHA-256 of the archived text: 0209cd928ab406017948b6b7dc8659784e6b3f58cf58195d8f09728c595a300c
Stable URL of this page: https://metraipolis.com/documento/dc_de2ceca81ee2

How to cite

Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes: a BRAVO model-based evaluation — Europe PMC PMID:42273622 — Europe PMC (en), https://europepmc.org/article/MED/42273622 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_de2ceca81ee2 (Metraipolis archive dc_de2ceca81ee2, sha256 0209cd928ab406017948b6b7dc8659784e6b3f58cf58195d8f09728c595a300c)

BibTeX

@misc{dcde2ceca81ee2,
  title = {Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes: a BRAVO model-based evaluation — Europe PMC PMID:42273622},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42273622},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_de2ceca81ee2; sha256 0209cd928ab406017948b6b7dc8659784e6b3f58cf58195d8f09728c595a300c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42273622. Agents can read the archived copy with the MCP tool read_document.